ABSTRACT
Lung cancer is the worlds first cause of death by cancer. Locally advanced and metastatic non small cell cancers represent 2/3rd of cases at diagnosis and are of worst prognosis. We conducted a retrospective study of 202 patients to investigate the effect of chemotherapy on survival and quality of life. 95 patients received chemotherapy with VP16- CDDP [88%] or Gemcitabin-CDDP Improvement survival was observed in the chemotherapy group: 8 month IC 95% [6.6-9.3]4 month IC 95% [3.1-4.9] in the control group. Chemotherapy also had a good perfect on the quality of life with improvement of performance status symptoms and need of analgesic. However, although significant the role of chemotherapy in NSCLC remains modest and new therapeutic approaches are needed including prevention and early detection which are probably more effective and cheaper
Subject(s)
Humans , Male , Female , Lung Neoplasms/drug therapy , Survival Rate , Retrospective Studies , Quality of Life , Antineoplastic Combined Chemotherapy Protocols , Etoposide , CisplatinABSTRACT
The incidence of chronic obstructive pulmonary disease [COPD] is increasing particularly in developing countries. Their prognosis depend on several factors in particular the one second forced expiratory volume [FEV1] decline. To study FEV1 decline speed and factors affecting it, we carried out a retrospective study of 160 cases of COPD in stable state and heaving at least two FEV1 measures at 6 months of interval in the minimum and. The middle age was 63 +/- 12 yr, 52% was former smokers and 46% current smokers, with middle of 50 +/- 27pack-yr.The FEV1 decline was calculated by linear regression models. The decline average in FEV1 with time was 72 +/- 55 ml/yr. Absolute value was higher than 30 ml/yr therefore more accelerated than general population in 79% of cases. We confirmed by multivariate analysis that age and smoking habit and increased the FEV1 decline. However this last correlated with FEV1% predicted. We concluded that the decline of FEV1 is higher in COPD that in the general population and I slowing it needs smoking stop
Subject(s)
Humans , Male , Female , Respiratory Function Tests , Forced Expiratory Volume , Retrospective Studies , SmokingABSTRACT
Prognostic factors have a pivotal role in clinical oncology. They are helpful in the selection of treatment, provide insights into the disease process and the therapeutic response. The number of possibly useful prognostic factors in the lung cancer is large. This study attempts to observe the survival of non small cell lung cancer [NSCLC] and to find prognostic factors and other variables potentially associated with outcome of lung cancer. It's a retrospective study based on 211 patients with NSCLC. Median survival was 6 months with 95% confidence interval [4,2 - 7,8]. Overall 3 and 5 year survival were respectively 8,3% and 5,2%. Various Prognostic factors have been identified through univariate [Koplan-Meier] then multivariate [Cox] analyses. In addition to the clinical factors such as age, disease extent and performance status, other variables were found of significant prognostic value, like pre-therapeutic leukocyte level. Survival was significantly improved with surgery, radiation and also with chemotherapy, mainly in advanced. stage [IIIB and IV]